Disc MedicineIRON -0.30%34 Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates IRON with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 146 Biotechnology companies, Disc Medicine ranks worse than 684930.82% on this metric.
As of today (2026-06-26), the Forward Annual Dividend Yield of Disc Medicine is 0.00%.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Disc Medicine is 0.00%.
IRON's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Disc Medicine (NAS:IRON) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Disc Medicine Forward Dividend Yield % Related Terms
IRON vs DFTX, ARQT, MLYS: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Disc Medicine's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disc Medicine Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Disc Medicine's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Disc Medicine's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Disc Medicine (IRON) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Disc Medicine and its competitors. According to the industry distribution chart, Disc Medicine ranks #999999 out of 146 companies in the Biotechnology industry.
Is Disc Medicine's Forward Dividend Yield % too high?
Disc Medicine's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Disc Medicine ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Disc Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's Forward Dividend Yield % compare to DFTX and ARQT?
According to the Biotechnology industry distribution chart, Disc Medicine ranks #999999 out of 146 companies for Forward Dividend Yield %. This places Disc Medicine in the lower half of its industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Disc Medicine and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disc Medicine's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Disc Medicine's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Disc Medicine (IRON), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
34GF Score
Get the complete analysis for IRON
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRON has been successfully added to your 